Evidence map›Paper›PMID 40765143›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2025

Optogenetic vision restoration in the face of secondary and tertiary remodeling in the rd1 mouse retina.

Steven Hughes, Jessica Rodgers, Moritz Lindner, Stuart N Peirson, Robert J Lucas, Mark W Hankins

Abstract read
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Steven HughesNuffield Laboratory of Ophthalmology, Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, UK.
Jessica RodgersFaculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Moritz LindnerNuffield Laboratory of Ophthalmology, Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; Institute of Physiology and Pathophysiology, Department of Neurophysiology, Philipps-Universität Marburg, Marburg, Germany; Department of Ophthalmology, Philipps-Universität Marburg, 35037 Marburg, Germany.
Stuart N PeirsonNuffield Laboratory of Ophthalmology, Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, UK.
Robert J LucasFaculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. Electronic address: robert.lucas@manchester.ac.uk.
Mark W HankinsNuffield Laboratory of Ophthalmology, Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, UK. Electronic address: mark.hankins@eye.ox.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Photoreceptor loss in retinal degeneration is followed by progressive remodeling of the surviving retina, which may present a barrier to vision restoration. To determine the impact of remodeling on the retina's suitability for therapeutic interventions, we track changes in visual code produced by the optogenetic actuator ReaChR expressed in ON-bipolar cells of the rd1 mouse at 3, 5, 9, and 12 months. Anatomical analyses confirm that these ages encompass phase II (photoreceptor degeneration) to phase III (inner retinal thinning, dysmorphia, pigment epithelium infiltration) remodeling. Multi-electrode array recording from retinal ganglion cells reveals that ReaChR-driven responses to a range of visual stimuli are stable across this age range. Response amplitude, sensitivity, and reproducibility all increased between 3 and 5 months, remaining consistent thereafter. Receptive field sizes, contrast sensitivity, and temporal frequency tuning showed minor changes with age. The diversity of retinal ganglion cell coding was maintained, reflected by the diversity captured by unsupervised functional clustering, with 11 distinct visual channels retained across ages. Our data indicate that remodeling does not significantly impair, and at early stages may even enhance, the surviving retina's ability to support visual restoration. Clinical intervention thus remains viable throughout remodeling, suggesting a wide window in disease progression for therapeutic benefit.

Indexed as

OptogeneticsRetinaRetinal DegenerationVision, OcularAnimalsDisease Models, AnimalMiceRetinal Ganglion Cellsbipolar celldegenerationeyegene therapyoptogeneticsremodelingretinavision restoration

Identifiers

PMID40765143
PMCPMC12628169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.